Posted by EarlyWakening on December 26, 2002, at 23:10:32
Aprepitant is the generic name for MK-869.
It's in Phase III trials for depression, but it looks likely to be approved first for chemotherapy-induced nausea and vomiting, potentially by late Summer.Theoretically, once it is approved for that indication, a physician could prescribe it for depression as well.
----------------------
FDA Grants Priority Review for EMEND™, Merck's Investigational
Medicine for Prevention of Chemotherapy-Induced
Nausea and Vomiting
UPPER GWYNEDD, Pa., Dec. 6, 2002 - Merck & Co., Inc. announced today that the U.S. Food and Drug Administration has assigned a six-month priority review to the company's New Drug Application (NDA) for EMEND™ (aprepitant), an investigational Substance P neurokinin-1 (NK-1) receptor antagonist studied in combination with other anti-emetic agents for the prevention of chemotherapy-induced nausea and vomiting (CINV).
Merck's application for EMEND includes results from seven safety and efficacy studies that evaluated this once-daily, oral medicine in combination with other anti-emetic drugs in patients with acute (0 to 24 hours) and delayed (2 to 5 days) nausea and vomiting associated with single and repeated courses of highly emetogenic chemotherapy, including cisplatin.Merck researchers have been studying investigational agents that block the binding of Substance P to NK-1 receptors in the brain and gastrointestinal tract to determine if these agents may inhibit the nausea and vomiting frequently induced by anti-cancer medicines.
poster:EarlyWakening
thread:133306
URL: http://www.dr-bob.org/babble/20021223/msgs/133306.html